Risedronate Prevents Early Bone Loss Resulting from Whole-body Irradiation by Livingston, Eric
Clemson University
TigerPrints
All Theses Theses
7-2008
Risedronate Prevents Early Bone Loss Resulting
from Whole-body Irradiation
Eric Livingston
Clemson University, livinge@clemson.edu
Follow this and additional works at: https://tigerprints.clemson.edu/all_theses
Part of the Biomedical Engineering and Bioengineering Commons
This Thesis is brought to you for free and open access by the Theses at TigerPrints. It has been accepted for inclusion in All Theses by an authorized
administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.
Recommended Citation
Livingston, Eric, "Risedronate Prevents Early Bone Loss Resulting from Whole-body Irradiation" (2008). All Theses. 424.
https://tigerprints.clemson.edu/all_theses/424
  
 
RISEDRONATE PREVENTS EARLY BONE LOSS RESULTING FROM WHOLE-
BODY IRRADIATION 
________________________ 
A Thesis 
Presented to  
the Graduate School of  
Clemson University 
________________________ 
In Partial Fulfillment 
of the Requirements for the Degree 
Master of Science 
Bioengineering 
________________________ 
by 
Eric Wilson Livingston 
August 2008 
________________________ 
Accepted by: 
Dr. Ted A. Bateman, Committee Chair 
Dr. Delphine Dean 
Dr. Robin M. Graham 
  
ii 
 
ABSTRACT 
 
Osteoporosis is a condition characterized by a reduction in bone strength resulting 
in an overall increase in the risk of fracture.  There are many factors that contribute to the 
development of this condition, including ionizing radiation exposure.  Declines in bone 
volume and trabecular micro-architecture have been found following exposure to 
multiple types of radiation.  Past research has implicated reduction of osteoblast function 
and changes to vasculature as the primary sources of bone deterioration.  Recently, an 
early increase in osteoclast number was observed following exposure to low-energy X-
rays, identifying an increase in resorption as a possible cause and potential target for 
treatment.  The goals of this research are to further characterize the effects of X-rays on 
trabecular bone at multiple skeletal sites and time points, and assess the effectiveness of 
the bisphosphonate risedronate to mitigate the radiation-induced deterioration of the 
trabecular network. 
The results from this research indicate trabecular bone deterioration can occur 
within the first week following exposure to ionizing radiation, with no effects on cortical 
bone.  Serum markers of bone resorption are elevated at 7 days, indicating an early 
increase in osteoclast activity.  Importantly, bisphosphonate administration prevents the 
deterioration of trabecular bone volume and architecture at all time points and sites, 
further supporting earlier findings of osteoclast-mediated bone loss. 
In order to fully characterize the mechanisms resulting in bone loss, the radiation-
induced changes to bone cells should be studied more closely along with effects on bone 
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formation and resorption rates.  Earlier time points within the first week post-irradiation 
must be examined to determine the timeline when changes to bone cells produce 
functional declines in bone volume and architecture.  Additionally, the effects of these 
declines need to be correlated with changes in overall bone strength in order to determine 
the most appropriate dosing regimen for preventative and/or treatment therapies. The data 
from these studies may be useful in determining the most effective method of preventing 
fractures following radiotherapy. 
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CHAPTER 1 - INTRODUCTION 
 
Osteoporosis is a condition of reduced bone mass and overall bone quality, 
leading to an increase in the risk of fracture.  Bone quality encompasses both material and 
structural properties, such as trabecular bone micro-architecture and collagen content 
within the bone matrix.  Degradation of the bone matrix and structure leads to an increase 
in fragility and risk of fracture.  Osteoporosis can affect all segments of the population, 
though post-menopausal women are at the greatest risk.  Estimates suggest 50% of 
women and 25% of men over the age of 50 will suffer from an osteoporotic fracture.  
Current treatments for osteoporosis include anabolic and anti-resorptive therapies. 
Sex-hormone deficiency is the primary risk factor for osteoporosis, although 
many other factors can contribute to its development, including exposure to ionizing 
radiation.  Ionizing radiation has been shown to degrade bone properties and increase 
fracture risk through the inhibition of bone formation and damage to blood supply 
pathways.  Recent findings suggest an early increase in resorption may contribute to bone 
loss.  Standard osteoporosis treatments have not previously been used to prevent 
radiation-induced bone loss.  Indications of an osteoclast-regulated loss mechanism 
suggest treatment with anti-resorptive drugs may prevent fractures.  The goals of this 
research are to characterize the effects of ionizing radiation on bone micro-architectural 
properties, and examine the usefulness of anti-resorptive medications in preventing bone 
deterioration. 
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CHAPTER 2 - BACKGROUND 
 
2.1 General Bone Biology 
2.1.1 Components and Function 
Bone is a composite connective tissue consisting of multiple cell types and an 
extracellular matrix.  This matrix consists primarily of type I collagen fibers (90%), as 
well as other non-collagenous proteins and minerals.  The collagen fibers are oriented 
according to the direction of primary loading and provide tensile strength (Viguet-Carrin, 
Garnero et al. 2006).  The organic materials of the extracellular matrix are surrounded by 
mineral crystals in the form of hydroxyapatite.  These crystals attach to the collagen 
fibers via the non-collagenous proteins, providing compressive strength and hardness.  
Overall, the mineral crystals account for 70% of bone by mass, with the collagen fibers 
and non-collagenous proteins accounting for 22%.  The remaining 8% is attributed to 
water (Augat and Schorlemmer 2006). 
The skeletal system of mammals consists of two primary types of bone:  woven 
and lamellar.  Woven bone is formed rapidly with no consistent orientation of collagen 
fibers, resulting in a comparatively weak structure.  This type of bone is common within 
the developing fetus and functions as a place-holder during the fracture repair process 
(Currey 2003).  Woven bone is eventually replaced with lamellar bone.  Lamellar bone is 
organized into sheets of collagen and minerals and is much stronger than woven bone.  
Mature lamellar bone exists in two primary forms:  cortical (80%) and trabecular 
(20%).  Cortical bone is highly mineralized and comparatively static in terms of turnover 
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and remodeling.  It is present within the outer shell of all bones and the diaphyses of long 
bones.  In higher order mammals, the basic unit of organization is the osteon, which 
consists of multiple concentric layers of bone surrounding a vascular (Haversian) canal.  
The diaphyses of long bones are composed of many continuous, circumferential lamellae 
(Figure 2.1). 
 
 
 
Figure 2.1. Basic cortical bone structure. 
(http://www.mc.vanderbilt.edu/histology/labmanual2002/labsection1/CartilageandBone0
3_files/image002.jpg) 
 
Trabecular (cancellous or spongy) bone is a micro-architectural lattice-work of 
small, interconnected struts found in the interior of bones (Figure 2.2).  This type of bone 
is most abundant in the epiphyses and metaphyses of long bones, and is present 
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throughout the interior of the cortical shell of flat bones.  Individual struts are typically 
structured as rods or plates, depending on the loading conditions.  Trabecular bone has a 
higher turnover rate than cortical bone and is significantly less mineralized (Heaney 
2003).  Accordingly, it is generally much more porous than cortical bone.  The 
percentage breakdown of cortical and trabecular bone varies throughout the skeleton.  For 
instance, the epiphyses and metaphyses of long bones contain much more trabecular bone 
than the diaphyses, which are almost entirely cortical bone. 
 
 
 
Figure 2.2. Trabecular (cancellous) bone. 
(http://www.ama-cmeonline.com/osteo_mgmt/module03/images/m3_02path_02.jpg) 
 
The skeletal system has several important functions.  Bones, along with muscles, 
provide the structural and mechanical framework necessary for movement and support of 
the body.  The skeleton also plays a vital role in the protection of the body’s organ 
systems.  The ribs provide a protective framework for the heart and lungs while the skull 
protects the central component of the nervous system.  Bone is also responsible for 
storing the majority of the body’s supply of calcium.  Calcium is an important mineral 
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involved with many physiological activities, including muscle contraction.  The 
hydroxyapatite crystals of the bone extracellular matrix contain approximately 99% of 
the body’s total calcium supply.  As it is needed, calcium is released into the blood 
stream and distributed to the appropriate regions of the body (Specker 1996).  Lastly, the 
intramedullary cavities of long bones provide a protective environment for marrow and 
blood cell formation. 
 
2.1.2 Bone Remodeling 
Bone is a dynamic connective tissue capable of self-maintenance and self-repair. 
In the normal, healthy skeleton, old and damaged bone is constantly being resorbed and 
replaced with new bone.  This continuous cycle of resorption and formation is referred to 
as remodeling.  Osteoclasts and osteoblasts are the key cells involved in the remodeling 
process.  Osteoclasts are responsible for breaking down old or damaged bone.  The 
resorptive activity of these cells triggers the action of osteoblasts, which form new bone 
within the resorption cavity. 
 
2.1.2.1 Resorption Activity by Osteoclasts 
Osteoclasts are large, multinucleated cells responsible for the removal of old or 
damaged bone.  These cells arise from the precursors of the monocyte/macrophage cell 
line (Blair, Zhou et al. 2006).  Typically, osteoclasts are positioned in contact with the 
mineralized bone surface.  The primary identifying feature of osteoclasts is the ruffled 
border, a folding of plasma membranes in direct contact with the bone matrix.  This 
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border is surrounded by an actin protein ring which attaches to the bone surface and 
effectively seals off the region of bone to be resorbed (Vaananen, Zhao et al. 2000).  
Proton pumps create an acidic environment by releasing hydrogen ions along with 
lysosomal enzymes (tartrate-resistant acid phosphatase, cathepsin K, etc.) into the 
resorption compartment (Vaananen, Zhao et al. 2000).  The enzymes digest the collagen 
and bone matrix within the sealed region.  Hydroxyapatite crystals are dissolved by the 
acid environment (Zaidi, Pazianas et al. 1993).  The dissolution of the bone matrix forms 
a resorption cavity referred to as a Howship’s lacuna (Figure 2.3). 
 
 
 
Figure 2.3. Osteoclast within a Howship’s lacuna. 
(http://herkules.oulu.fi/isbn9514267761/html/graphic66.png) 
 
2.1.2.2 Formation of Bone by Osteoblasts 
Osteoblasts are cells that typically line the surface of bone and are responsible for 
the formation of new bone.  These cells arise from mesenchymal stem cells within the 
bone marrow.  Progenitor cells differentiate into pre-osteoblasts and ultimately, mature 
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osteoblasts under the regulation of cytokines and growth factors (Lian and Stein 1995).  
Osteoblasts lining bone surfaces are directly connected, allowing communication 
between individual cells (Stains and Civitelli 2005).  Osteoblasts are activated via a 
signal once bone resorption at a site is complete.  New, un-mineralized bone matrix 
(osteoid) is laid down within the resorption cavity.  The new matrix begins to mineralize 
over the next 5-10 days, and continues to do so until approximately 60% of the cavity is 
filled.  Secondary mineralization then begins and can continue for years thereafter 
(Davison, Siminoski et al. 2006).  Once the formation process is complete, the majority 
of osteoblasts die via apoptosis.  Others become trapped within the bone matrix during 
the mineralization process, becoming osteocytes.  Osteocytes are responsible for the 
maintenance of bone and exist within lacunae or along the quiescent surface of bone.  
These cells communicate with each other and with surface-lining osteoblasts, playing a 
vital role in the mineralization process as well as the bone matrix response to mechanical 
loading (Rodan 1992). 
 
2.1.2.3 Remodeling Process 
The bone remodeling process consists of five primary stages:  quiescence, 
activation, resorption, reversal, and formation (Parfitt 1984).  The resting state of bone is 
referred to as quiescence.  The surface of the bone is lined with flattened osteoblasts.  
Upon activation of the remodeling mechanisms, the surface-lining cells retract and 
expose the bone surface.  Circulating pre-osteoclasts are attracted to the exposed surface 
and fuse into mature, multinucleated osteoclasts.  The osteoclasts are then activated and 
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begin the resorption process.  Once resorption is complete, osteoblasts are signaled and 
converge at the resorption site to begin laying down new osteoid.  The new bone matrix 
becomes mineralized over time and the bone surface returns to the quiescent state (Figure 
2.4). 
 
 
 
Figure 2.4. Bone remodeling cycle. 
(http://www.umich.edu/news/Releases/2005/Feb05/bone.html) 
 
The remodeling process is regulated by many molecular elements, such as 
hormones, cytokines, and growth factors along with bone cells (osteoclasts, osteoblasts) 
(Mundy 1993; Fernandez-Tresguerres-Hernandez-Gil, Alobera-Gracia et al. 2006).  In 
healthy individuals, remodeling is balanced between resorption and formation, as 
approximately 2% of cortical bone and 15-20% of trabecular bone is renewed each year, 
giving an overall rate of 5-10% (Fernandez-Tresguerres-Hernandez-Gil, Alobera-Gracia 
et al. 2006).  In normal remodeling, the resorption process is always followed by the 
formation of new bone.  As such, stimulation or inhibition of either of these processes 
results in a similar response in the other process.  Disruption of this balance results in the 
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onset of many skeletal diseases, including osteoporosis, osteopetrosis, Paget’s disease, 
and malignant bone metastases (Blair, Zhou et al. 2006). 
 
2.1.3 Biomechanics of Bone 
Bone plays an important role as the structural framework for support and 
movement of the body.  Individual bones function as levers for muscle contractions and 
provide support during movement.  Strength is the key measure of bone functionality 
within biomechanics and serves as the primary indicator of fracture susceptibility (Turner 
2002).  Bone strength is influenced by several factors, including overall mass, material 
properties, and structural properties (micro-architecture, moment of inertia, etc.) 
(Ammann and Rizzoli 2003; Bouxsein 2005; Augat and Schorlemmer 2006).  In the 
clinical setting, measures of bone mineral density as determined using dual-energy X-ray 
absorptiometry (DEXA) are used to estimate strength.  DEXA alone, however, does not 
correlate directly to whole bone strength.  Estimates indicate mineral content and porosity 
account for only 60% of bone bending strength (Currey 1999).  The remaining percentage 
is determined by a combination of material and structural properties.  These properties 
are collectively referred to as ‘bone quality’ and, along with the rate of remodeling, must 
be considered in order to accurately estimate bone strength (Burr 2004). 
 
2.1.3.1 Bone Material Properties 
Bone is a composite tissue composed primarily of type I collagen (22%) and 
mineral crystals (70%) (Augat and Schorlemmer 2006).  Reductions in collagen quality 
10 
 
have little to no effect on the elastic modulus of bone or stiffness.  However, collagen 
plays a vital role in the inhibition of crack propagation.  Accordingly, toughness (energy 
absorbed to fracture) and tensile strength are positively correlated to collagen quality.  
Reduction in quality has a significant negative impact on these parameters (Burr 2002).  
The stability and cross-linking of the collagen fibers also affect strength, as studies have 
shown a positive correlation between the number of cross-links and overall toughness 
(Zioupos, Currey et al. 1999).  The extent of collagen cross-linking decreases with age, 
leading to an increase in fracture susceptibility (Zioupos, Currey et al. 1999).  The 
stiffness of bone is directly proportional to the degree of mineralization (Bouxsein 2005).  
The mineral crystals within bone are primarily in the form of hydroxyapatite 
(Ca10(PO4)6(OH)2).  These crystals nucleate within the collagen fibrils, and their size and 
distribution directly affect density and strength.  The size of the crystals tends to increase 
with age, causing bone to become more brittle (Augat and Schorlemmer 2006). 
In healthy bone, the ratio of mineral and collagen content is sufficient to 
withstand normal loading within everyday life.  However, deviations in the degree of 
mineralization can lead to negative effects on bone strength.  A low turnover rate causes 
bone to become hyper-mineralized and damage to accumulate within the matrix. With 
suppressed remodeling, the bone material becomes more homogeneous, allowing cracks 
to propagate more easily than otherwise (Augat and Schorlemmer 2006).  This leads to a 
decrease in toughness and ultimate strain when loaded in tension (Currey, Brear et al. 
1996; Augat and Schorlemmer 2006).  Increases in turnover can be equally as harmful, 
albeit for different reasons.  High turnover rates lead to hypo-mineralized bone.  
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Toughness and tensile strength are increased, but stiffness is greatly reduced, as seen in 
individuals suffering from osteomalacia or rickets. 
 
2.1.3.2 Bone Structural Properties 
The distribution of mass plays an important role in the determination of bone 
structural properties.  In the simplest terms, bigger is better, meaning large bones are 
generally capable of supporting large loads (Bouxsein 2005).  However, without 
accounting for the distribution, bone mass alone is not a direct indicator of strength.  The 
thickness of the cortical shell, cross-sectional area, and moment of inertia have been 
shown to account for up to 70% of whole bone strength (Augat and Schorlemmer 2006). 
The ability of bone to resist bending and torsional loading is directly proportional to 
moment of inertia.  Polar moment of inertia is often used to indicate strength, as it takes 
into account the distribution of mass relative to both cross-sectional axes.  While keeping 
cross-sectional area constant, increasing the diameter of a bone distributes mass farther 
from the neutral axis (higher moment of inertia) and increases the maximum bending 
load that can be applied without failure (Figure 2.5).  As such, a small diameter bone with 
a thick cortical shell is not necessarily the optimum structural configuration. 
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Figure 2.5. Illustration of geometric influences on bone strength. (Bouxsein 2005) 
 
The micro-architecture of trabecular bone is also a key component in bone 
strength determination.  Trabecular bone is a highly porous, interconnected lattice-work 
of struts.  These struts are typically structured as either cylindrical rods or parallel plates, 
and are important in the distribution of forces throughout the bone structure.  Trabecular 
bone is found within the epiphyses and metaphyses of long bones and within the cortical 
shell of flat bones.  Common measures of trabecular bone micro-architecture include 
bone volume fraction (BV/TV), connectivity density, structural model index (SMI), 
trabecular number, trabecular thickness, and trabecular separation.  Trabecular volume 
fraction, connectivity density, and structural model index measure properties of the entire 
trabecular structure.  Trabecular number, thickness, and separation are associated with 
individual struts. 
Bone volume fraction is a percentage measure of the amount of trabecular bone 
present.  Together with density, bone volume is a strong indicator of overall strength 
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(Keaveny and Hayes 1993; Currey 2001).  Connectivity density measures the number of 
trabecular connections per unit volume.  Qualitatively, connectivity is important in the 
efficient transfer of loads throughout the bone structure (Figure 2.6).  High connectivity 
indicates the majority of struts within the network are supported (Borah, Gross et al. 
2001).  The strength of a strut is inversely proportional to the square of the unsupported 
length (Davison, Siminoski et al. 2006), meaning strength increases with connectivity.   
 
 
 
Figure 2.6. Connectivity of trabecular bone. 
(http://www.designfax.net/archives/0904/IMAGES/D0409-141a-big.gif) 
 
Loss of individual struts reduces connectivity and strength.  The removal of 
horizontal struts is particularly damaging, as the likelihood of buckling failure of the 
remaining vertical struts becomes increased (Bouxsein 2005) (Figure 2.7).  Trabecular 
number and separation are closely associated with connectivity, as a reduction in number 
will likely lead to a reduction in connectivity and an increase in separation.  Trabecular 
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thickness has a smaller effect on strength (Bouxsein 2005), and is related more closely to 
the structural model index. 
 
 
 
Figure 2.7. Effect of trabecular struts on buckling strength. (Bouxsein 2005) 
 
Structural model index measures the ratio of rod-like to plate-like trabeculae.  
Bone volume fraction is negatively correlated with SMI, as regions of high trabecular 
bone volume typically have a higher number of thick, plate-like trabeculae (lower SMI) 
(Hildebrand, Laib et al. 1999).  Accordingly, lower values of SMI are associated with 
higher measures of bone strength.  Trabecular thickness tends to decrease as plate-like 
elements are restructured as rod-like.  As mentioned earlier, trabecular thinning is not as 
harmful to strength as is the complete removal of a trabecular strut.  However, an 
increase in SMI coupled with a decrease in trabecular thickness can be indicative of bone 
loss associated with osteoporosis (Borah, Dufresne et al. 2004). 
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2.1.3.3 Turnover Influence on Biomechanics 
The rate of bone remodeling has a substantial effect on bone quality (Heaney 
2003).  Under normal circumstances, bone resorption and formation are balanced, 
ensuring sufficient strength to withstand normal loading is maintained.  If this balance is 
disrupted, harmful changes in bone material and structural properties occur, as seen in 
aging individuals or those suffering from a skeletal disease.  Non-normal rates of 
remodeling, whether high or low, compromise overall bone strength.  Elevation of the 
normal bone turnover rate produces an increase in resorption, decrease in mass and 
mineralization, and a net reduction in bone strength (Parfitt 2002; Heaney 2003; Borah, 
Dufresne et al. 2004).  An extreme case of this mechanism is manifested as Paget’s 
disease.  Paget’s disease is characterized by an abnormally high rate of bone turnover, 
resulting in the formation of irregular woven bone and an overall increase in density.  
However, as woven bone is overly ductile and generally weaker than lamellar bone, 
skeletal strength is greatly compromised (Raisz 1999). 
A lower than normal turnover rate adversely affects bone in other ways.  Normal 
remodeling is necessary for the repair of micro-fractures and the renewal of old, brittle 
bone.  Turnover suppression leads to the accumulation of damage within the bone matrix 
and allows older bone to become hyper-mineralized, reducing the overall quality and 
strength of the bone.  This mechanism is most clearly identified with osteopetrosis, a 
disease characterized by overly dense, brittle bones (Tolar, Teitelbaum et al. 2004).  
Osteopetrosis is induced by a loss or impairment of osteoclast function resulting in 
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abnormal architecture (Raisz 1999).  As a result, individuals afflicted with osteopetrosis 
are generally much more susceptible to fracture than those with normal bone.   
 
2.2 Osteoporosis 
Osteoporosis is a skeletal condition of reduced bone mass coupled with 
degradation of micro-architectural properties (Figure 2.8), resulting in overall weaker 
bones and an increase in fracture susceptibility (Consensus development conference 
1993; NIH Consensus Development Panel 2001).  Osteoporotic fractures typically occur 
in the absence of trauma, and are most common at the hips, spine, and wrists.  Measures 
of bone mineral density are the primary tool used for clinical diagnosis.  Individuals with 
bone density scores more than 1 standard deviation below the mean for a young adult are 
classified as ‘at risk’ for the disease, while results more than 2.5 standard deviations 
below the mean indicate the patient has osteoporosis. 
 
 
 
Figure 2.8. Comparison of normal and osteoporotic bone. (Dufresne, Chmielewski et al. 
2003) 
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Osteoporosis is a major public health concern.  The condition currently affects 
more than 10 million Americans with another 34 million classified as ‘at risk’ (National 
Osteoporosis Foundation 2008).  Approximately 50% of women and 25% of men over 
the age of 50 will suffer from an osteoporotic fracture within their lifetime.  The number 
of fractures related to osteoporosis is expected to reach 3 million per year by 2025 
(National Osteoporosis Foundation 2008).  These fractures are often treated with invasive 
surgeries, leading to high levels of morbidity and mortality, particularly in the case of hip 
fractures.  Nearly ¼ of hip fracture patients die within the first year following fracture, 
and only 15% are able to walk across a room unaided at 6 months (National Osteoporosis 
Foundation 2008).  Many patients require long-term care, creating a large financial 
burden on both the healthy and afflicted populations. 
 
2.2.1 Mechanisms of Osteoporosis 
There are many risk factors for osteoporosis, including menopause, aging, and 
glucocorticoid therapies.  Glucocorticoids are used as strong anti-inflammatory agents.  
These drugs have been shown to reduce bone strength by suppressing formation (Lems 
2007).  Apoptosis of osteocytes and osteoblasts is induced, severely limiting the 
production of the organic bone constituents. 
Estrogen deficiency has been implicated as the primary cause of osteoporosis in 
post-menopausal women and a contributor to development of the condition in men 
(Riggs, Khosla et al. 2002).  Reduction in estrogen production unbalances the normal 
turnover mechanism in the direction of resorption, leading to substantial bone loss.  The 
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rise in resorption levels results from an overall increase in osteoclast production and 
activity (Manolagas 2000).  This increase in osteoclast activity can lead to an increased 
turnover rate, deep resorption lacunae, and deterioration of trabecular bone micro-
architecture.  Specifically, trabecular plates become perforated and disconnected as they 
are restructured into rods.  Osteocytes and osteoblasts are also affected by lower estrogen 
levels.  The survival rate of osteocytes decreases, as does the ability of osteoblasts to 
detect and repair micro-fractures (Manolagas 2000). 
Regardless of cause, osteoporosis tends to worsen with age.  The body’s ability to 
respond to skeletal injury decreases with age, leading to the accumulation of micro-
fractures and an increase in porosity throughout (Schaffler, Choi et al. 1995).  Osteoblast 
recruitment to damage sites is markedly reduced, allowing micro-damage to accumulate 
more rapidly than the repair processes can handle.  Micro-architectural deterioration 
continually decreases, as does whole bone strength (Schaffler, Choi et al. 1995). 
 
2.2.1.1 Radiation-Induced Osteoporosis 
Humans are exposed to radiation from background sources throughout their lives.  
The received doses, however, are typically not large enough to produce significant health 
problems (Todd 2003).  Exposure to large doses, such as those used in cancer 
radiotherapy, is potentially very damaging to many of the body’s systems, including the 
skeletal system.  Nearly 1.5 million new cases of cancer are expected in 2008, along with 
over 500,000 deaths.  Approximately 60% of all cancer patients will undergo 
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radiotherapy, placing an increasingly large segment of the population at risk to the side-
effects of radiation exposure. 
Fracture following radiotherapy is a well-documented phenomenon.  Fractures at 
multiple sites throughout the body have been noted following radiation therapy, including 
the hips, ribs, clavicle, and humerus (Howland, Loeffler et al. 1975; Pierce, Recht et al. 
1992; Grigsby, Roberts et al. 1995; Bliss, Parsons et al. 1996; Mumber, Greven et al. 
1997; Moreno, Clemente et al. 1999).  Additionally, the relative risk of fracture within 
the radiation-treated population is much higher (Baxter, Habermann et al. 2005).  
Deterioration of trabecular bone micro-architecture has been found in rodents following 
exposure to several types of radiation, including those used in the clinical setting (gamma 
rays, protons) (Hamilton, Pecaut et al. 2006; Bandstra, Pecaut et al. 2008), as has reduced 
bone mineral content in humans (Nishiyama, Inaba et al. 1992).  Micro-architecture and 
mineral content are both key components to whole bone strength (Ammann and Rizzoli 
2003; Bouxsein 2005; Augat and Schorlemmer 2006).  As such, the loss of either can 
have a substantial negative impact on strength. 
The mechanisms leading to the noted loss of bone are not yet fully identified, and 
are currently under investigation within our laboratory.  Past research identifies reduced 
osteoblast functionality and damage to vasculature as the root causes of bone 
deterioration (Mitchell and Logan 1998; Okunieff, Wang et al. 1998; Gal, Munoz-
Antonia et al. 2000; Sakurai, Sawada et al. 2007).  A recent study within our laboratory 
suggests osteoclast activity is increased following irradiation (Willey et al. Radiat Res, 
accepted 6/08).  These findings will be explored further within the next chapter. 
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2.2.2 Osteoporosis Treatments 
The ultimate osteoporosis treatment goal is to build new bone with normal 
structure and quality (Rizzoli 2007).  Currently, there are two primary types of treatment 
available for osteoporosis:  anti-resorptive and anabolic therapies.  Anti-resorptives 
function by inhibiting osteoclast resorptive ability.  Anabolic treatments induce bone 
formation.  With the identification of decreased sex hormone production as the primary 
cause of osteoporosis, some type of hormone replacement therapy would seem to be the 
obvious method of treatment.  However, a rise in the risk of breast cancer and 
cardiovascular diseases has been linked to hormone replacement therapy (Couzin 2003).  
Anti-resorptives, namely bisphosphonates, are the most common osteoporosis treatments 
currently used. 
 
2.2.2.1 Anti-resorptive Therapy (bisphosphonates) 
Bisphosphonates function by binding to the exposed mineral surface of bone 
(Rogers, Watts et al. 1997).  Bone resorption is affected in several ways.  
Bisphosphonates disrupt the ability of resorbing cells to attach to the bone surface 
effectively (Rogers, Watts et al. 1997).  The ruffled border of the osteoclast becomes 
unable to form a seal with the bone surface, allowing the secreted mineral-dissolving 
solution to leak away from the bone (Azuma, Sato et al. 1995).  In addition, 
bisphosphonates have been shown to act directly on osteoclasts.  The drug is internalized 
by osteoclasts and can severely limit the resorptive capability of the cell or induce 
apoptosis (Azuma, Sato et al. 1995; Rogers, Watts et al. 1997). Bisphosphonates have 
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also been shown to negatively affect osteoclast differentiation and recruitment to bone 
surfaces (Azuma, Sato et al. 1995; Rodan and Fleisch 1996; Rogers 2003).  It has 
recently been suggested that osteoblasts and osteocytes are also affected by 
bisphosphonates.  Small concentrations have been shown to stimulate osteoblasts and 
inhibit osteocyte apoptosis, although the effects on osteoblasts are likely due to the 
normal coupling mechanism of osteoblasts and osteoclasts (Russell, Watts et al. 2008). 
Clinically, bisphosphonates are known to have positive effects on bone turnover, 
mineralization, micro-architecture, and fracture risk (Borah, Gross et al. 2001; Borah, 
Dufresne et al. 2004; Rizzoli 2007).  However, prolonged use can also inhibit formation.  
Upon binding to the bone mineral surface, bisphosphonate molecules can remain within 
the skeletal system for several years.  The anti-resorptive effects have been demonstrated 
for 5 years following the cessation of a 5-year treatment regimen (Rizzoli 2007).  Long-
term accumulation has the potential to severely inhibit the normal bone turnover 
mechanism, resulting in overly porous and fragile bone. 
 
2.2.2.2 Anabolic Therapy 
Recombinant human parathyroid hormone (rhPTH) was approved by the FDA as 
an anabolic treatment option in 2002.  The drug functions by stimulating bone formation 
on previously quiescent bone surfaces.  Anabolic therapy is typically used only in 
patients who already have multiple osteoporotic fractures (Benhamou 2007).  Increases in 
bone mineral density in the lumbar spine (9-13%) and femoral neck (3%) have been 
noted in post-menopausal women following PTH therapy (Neer, Arnaud et al. 2001).  
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Positive effects within trabecular bone have also been observed (Dempster, Cosman et al. 
2001).  PTH therapy can also significantly reduce the risk of both vertebral and non-
vertebral fractures (Neer, Arnaud et al. 2001).  PTH is not an ideal therapy for 
osteoporosis, however.  Administration currently requires a daily subcutaneous injection, 
which is much more inconvenient to the patient than the standard oral doses of 
bisphosphonates.  In addition, PTH stimulates osteoclast function through the normal 
coupling mechanism of osteoblasts and osteoclasts.  The associated increase in bone 
resorption at least partially inhibits the positive effects on bone formation and strength 
(Fu, Jilka et al. 2002). 
  
23 
 
CHAPTER 3 - THE USE OF RISEDRONATE AS A COUNTERMEASURE TO 
RADIATION-INDUCED BONE LOSS 
 
3.1 Abstract  
Bone loss is a known side-effect of exposure to ionizing radiation.  Recently, an 
early increase in osteoclast activity was identified as a possible cause of radiation 
atrophy.  In this study, mice were exposed to a 2 Gy whole-body dose of X-rays to 
quantify effects on trabecular micro-architecture and examine the effectiveness of 
bisphosphonate administration at mitigating bone loss.  C57Bl6/J mice were sacrificed at 
one, two, and three weeks post-irradiation.  Within each time point were three groups:  
non-irradiated controls, irradiated given placebo, and irradiated given risedronate 
(Actonel®; Procter and Gamble Pharmaceuticals).  Analysis using microCT found 
significant declines in trabecular bone volume and architectural properties at all time 
points within the tibia, femur, and fifth lumbar vertebra.  Serum levels of tartrate-resistant 
acid phosphatase (TRAP5b), a marker of bone resorption, were elevated at one week.  No 
changes were found in serum osteocalcin levels or cortical bone properties of the femoral 
mid-diaphysis.  Risedronate administration prevented trabecular bone deterioration at all 
sites and time points examined, and significantly reduced TRAP5b concentration to 
below-normal levels.  These findings support the hypothesis of an early, radiation-
induced increase in osteoclast activity, and provide the basis for a potential method of 
prevention of post-irradiation fractures. 
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3.2 Introduction 
Osteoporosis is a result of declines in density as well as significant deterioration 
of the micro-architectural properties of bone, leading to increased fracture risk 
(Consensus development conference 1993; NIH Consensus Development Panel 2001).  
Although menopause is the greatest risk factor for osteoporosis, many other factors 
contribute to the etiology of this condition (NIH Consensus Development Panel 2001; 
National Osteoporosis Foundation 2008).  Among these factors may be the relatively 
unexplored effect of ionizing radiation on skeletal properties. 
Radiation therapy has been linked to fractures at several skeletal sites, including 
the clavicle, humerus, ribs, and pelvis (Howland, Loeffler et al. 1975; Pierce, Recht et al. 
1992; Grigsby, Roberts et al. 1995; Bliss, Parsons et al. 1996; Mumber, Greven et al. 
1997; Moreno, Clemente et al. 1999).  The vast majority of these fractures have been 
documented in the hip.  Baxter et al. found a marked increase in the rate of hip fracture in 
post-menopausal women receiving radiation treatment for pelvic tumors (Baxter, 
Habermann et al. 2005).  This is particularly alarming, as from this demographic, hip 
fractures can result in substantial morbidity, loss of independence, and approximately a 
15-20% mortality rate within the first year of injury (NIH Consensus Development Panel 
2001; National Osteoporosis Foundation 2008). 
The incidence of hip fractures following radiotherapy is a great concern, as 
improvements in diagnosis and treatment are increasing the 5 year cancer survival rate.  
In 2008, an estimated 500,000 new cases of pelvic cancers will be diagnosed.  Of these 
new cases, approximately 60% will receive radiation therapy (National Cancer Institute 
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2007).  Therefore, the possibility that ionizing radiation can directly serve as a cause of 
pathological bone loss or reduced quality of bone should be explored.   
Atrophy following irradiation has been documented as a late response in clinical 
studies (Nishiyama, Inaba et al. 1992) as well as animal trials using clinically-relevant 
types of radiation at relatively low (i.e. 1 Gy protons), acute doses (Hamilton, Pecaut et 
al. 2006; Bandstra, Pecaut et al. 2008).  Much of the research to date has focused on 
damage to vasculature and bone-forming cells (Mitchell and Logan 1998; Okunieff, 
Wang et al. 1998; Gal, Munoz-Antonia et al. 2000; Sakurai, Sawada et al. 2007).  
Significant reduction in blood flow to irradiated regions has been documented (Okunieff, 
Wang et al. 1998).  This reduction in flow may contribute to long-term bone damage, 
including atrophy (Mitchell and Logan 1998; Hopewell 2003).  It is believed that the 
function of osteoblasts is impaired sufficiently to inhibit the production of bone 
extracellular matrix (Mitchell and Logan 1998).  A significant reduction in bone 
formation coupled with an increase in resorption following high-dose irradiation has been 
observed (Sugimoto, Takahashi et al. 1991), as well as decreased osteoblast number, 
proliferation, differentiation, and collagen production from both in vivo and in vitro 
models (Gal, Munoz-Antonia et al. 2000; Sawajiri, Mizoe et al. 2003; Ma, Shi et al. 
2007; Sakurai, Sawada et al. 2007).  
At present, few researchers have studied radiation effects on osteoclasts, and the 
results from those who have are inconsistent.  Sawajiri et al. observed a long-term 
decrease in osteoclast numbers following high-dose irradiation with carbon ions and 
gamma rays, with inconclusive results in the short-term (Sawajiri, Mizoe et al. 2003).  
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Others have noted no change in osteoclast numbers following irradiation (Goblirsch, 
Mathews et al. 2004; Vit, Ohara et al. 2006).  Recently, significant increases in osteoclast 
number and activity have been observed following a whole-body dose of X-rays at 3 days 
post-irradiation, though without a loss of bone volume or trabecular parameters as 
quantified via micro-computed tomography (Willey et al. Radiat Res, accepted 6/08).  An 
acute increase in osteoclast activity may at least contribute to long term bone atrophy.  
This connection between early osteoclast activation and radiation atrophy would provide 
a potential pharmacological target for treatment using bisphosphonates, specifically 
risedronate (Actonel®; Procter and Gamble Pharmaceuticals). 
Bisphosphonates are currently the most common drugs used in the treatment of 
osteoporosis. These drugs function by lessening bone turnover through the inhibition of 
osteoclast activity (Russell 2007).  Bisphosphonates have been shown as an effective 
treatment option for hypercalcemia, fractures, bone pain, and other bone-related problems 
associated with cancer (Guise and Mundy 1998; Body and Mancini 2002; Ross, Saunders 
et al. 2003; Russell 2007).  If radiation were to induce an early increase in osteoclast 
activity, the action of bisphosphonates may prevent subsequent post-exposure atrophy.  
The aims of this research were to:  a) characterize the early effects of ionizing radiation 
on bone properties by examining multiple time points and skeletal sites, and b) evaluate 
the effectiveness of risedronate at preventing the osteoclast-mediated degradation of bone 
micro-architecture. 
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3.3 Methods 
3.3.1 Animals and Study Design 
One hundred fifteen 20-week-old female C57BL/6 mice (Taconic Farms, Inc., 
Hudson, NY) were examined in this study.  The mice were received at 15 weeks of age 
and allowed to acclimatize to their environment and reach skeletal maturity at 20 weeks 
of age (Ferguson, Ayers et al. 2003).  The animals were grouped to control for body 
mass.  Ten groups were studied (n=10-12 per group).  In addition to baseline controls 
(n=10), groups of mice were euthanized at one (n=36), two (n=36), and three (n=33) 
weeks following radiation exposure.  Within each time point, mice were divided evenly 
into three treatments:  non-irradiated given placebo (NR+PL), irradiated given placebo 
(IR+PL), and irradiated given risedronate (IR+RIS).  All subsequent procedures were 
approved by the Institutional Animal Care and Use Committee at Clemson University. 
 
3.3.2 Treatments: Irradiation and Risedronate 
The mice in the IR+PL and IR+RIS groups were exposed to a dose of X-rays 
using a portable industrial unit (Philips K140Be) operating at 140 kVp.  All mice were 
anesthetized prior to exposure with isoflurane.  Mice in the radiation groups were placed 
4.4 cm below the shield of the X-ray source and exposed to a 2 Gy whole-body dose at a 
rate of 1.36 Gy/min.  Non-irradiated mice were kept under anesthesia for an equivalent 
period of time.  Beginning on the day of irradiation, each animal in the study groups 
received a subcutaneous injection of either risedronate (Actonel®; Procter and Gamble 
Pharmaceuticals) or placebo (PBS) every other day.  Each mouse in the IR+RIS groups 
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received a dose of 30 µg/kg body mass every other day.  Mice in the NR+PL and IR+PL 
groups received an equivalent volume of PBS.  
The baseline control animals were sacrificed the day following the radiation 
exposures.  The remaining animals were sacrificed at 1, 2, or 3 weeks following radiation 
exposure.  At the time of sacrifice, each mouse was anesthetized using isoflurane.  Blood 
was collected for serum analysis by cardiac puncture and exsanguination followed by 
cervical dislocation to ensure death.  The left hind limb and vertebral column were 
collected for trabecular and cortical bone analysis.  The left hind limb was stored in a 
10% formalin solution.  The vertebral column was frozen in saline-soaked gauze 
 
3.3.3 Bone Architectural Analyses 
After 48 hours, the left hind limb was removed from formalin solution and stored 
in 70% ethanol, with the femur and tibia cleaned of nonosseous tissue.  The tibiae were 
then analyzed using micro-computed tomography (µCT20; Scanco Medical AG, 
Bassersdorf, Switzerland).  A section of each tibia immediately distal to the epiphyseal 
plate measuring approximately 1 mm was scanned with a 9 µm voxel size.  Three-
dimensional images were reconstructed from all scans and used to evaluate trabecular 
bone properties.  Trabecular bone volume fraction (BV/TV), connectivity density 
(Conn.Dens), structural model index (SMI), trabecular thickness (Tb.Th), trabecular 
number (Tb.N), trabecular spacing (Tb.Sp), and bone mineral density (vBMD) were 
measured for each sample using Scanco analysis software. 
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The fifth lumbar vertebrae and femora analyses were performed similarly using 
microCT (µCT80; Scanco Medical AG, Bassersdorf, Switzerland).  The collected 
vertebra samples were removed from frozen storage and placed in ethanol solution.  The 
fifth lumbar vertebra was isolated using the microCT X-ray scout view and scanned in its 
entirety (~3.5 mm) with a 10 µm voxel size.  A section of the vertebral body measuring 
0.5 mm immediately superior to the caudal end plate was selected for analysis.  This 
region was chosen because of its relatively high trabecular bone density and to minimize 
morphological differences between samples.  Trabecular bone properties were evaluated 
for each sample.  The left femora were evaluated in 2 regions:  the distal metaphysis and 
the mid-diaphysis.  A 1 mm section immediately superior to the distal growth plate was 
scanned and used to evaluate trabecular bone properties.  A section of the mid-diaphysis 
measuring approximately 0.3 mm was scanned and evaluated to determine cortical bone 
volume (BV), cortical porosity (Ct.Po), and polar moment of inertia (pMOI). 
 
3.3.4 Serum Chemistry 
The collected serum samples were analyzed for markers of bone formation and 
resorption using ELISA kits for osteocalcin (Biomedical Technologies, Inc., Stoughton, 
MA) and tartrate-resistant acid phosphatase (TRAP5b) (Immunodiagnostic Systems, Inc., 
Fountain Hills, AZ), respectively.  The analyses were performed according to protocols 
provided by the manufacturers. 
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3.3.5 Statistical Evaluation 
All data are presented as mean ± standard error of the mean.  Significance was 
determined using SigmaStat version 3.5 (Systat Software Inc., Richmond, CA).  A one-
way analysis of variance with a Tukey post-hoc test was run on all results within each 
time point and across the duration of the study within NR+PL, IR+PL, IR+RIS.  Animal 
masses were evaluated further using a paired t-test to determine changes in animal mass 
for an individual group during the period of study.  The threshold for significance for all 
tests was set at a 5% probability of committing a Type I error (p=0.05). 
 
3.4 Results  
3.4.1 Animal Mass 
There were no differences in starting or ending animal masses between treatment 
groups, or across time in a given treatment (one-way-ANOVA).  Three groups had 
significant changes in animal mass during the course of the study as examined by paired 
t-test:  IR+PL animals euthanized at 2 (-2.5%) and 3 (-1.5%) weeks as well as IR+RIS 
animals euthanized at one week (+2%) (Table 3.1).   
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Table 3.1. Mean animal masses. 
 
Notes:  All data given as mean ± SEM  in grams. 
a 
difference between initial and final 
values (paired t-test p<0.05). 
 
 
3.4.2 Bone Architectural Analyses 
3.4.2.1 Proximal Tibia 
Analysis of trabecular bone properties within treatments across time of the 
proximal tibia identified no changes between baseline and non-irradiated control 
(NR+PL) groups.  Within irradiated (IR+PL) animals, there was a significant reduction in 
BV/TV (-18%; Figure 3.1) and vBMD (-12%; Table 3.2) at week 3 relative to week 1.  
Irradiated animals treated with risedronate (IR+RIS) showed a significant increase in 
vBMD (+12%) at week 3 compared to week 2. 
 
% Ch
Week 1 NR+PL 23.3 ± 0.2 23.4 ± 0.3 0.3
IR+PL 23.2 ± 0.5 23.0 ± 0.5 -0.9
IR+RIS 22.5 ± 0.2 23.0 ± 0.3 2.0 a
Week 2 NR+PL 23.1 ± 0.2 23.0 ± 0.4 -0.5
IR+PL 23.1 ± 0.3 22.6 ± 0.3 -2.5 a
IR+RIS 22.7 ± 0.4 22.7 ± 0.3 0.0
Week 3 NR+PL 22.9 ± 0.4 22.9 ± 0.5 -0.1
IR+PL 23.1 ± 0.4 22.7 ± 0.4 -1.5 a
IR+RIS 22.8 ± 0.3 22.7 ± 0.3 -0.4
Initial Final
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Figure 3.1. Trabecular bone volume of proximal tibia. 
 
Notes: * different from NR+PL within time point; + different from week 1 within 
treatment; # different from week 2 within treatment (ANOVA p<0.05). % difference given 
relative to NR+PL. 
 
Table 3.2. Trabecular bone properties of proximal tibia from µCT. 
 
Notes:  All data given as mean ± SEM. 
b
 different from NR+PL within time point. 
c
 different from week 1 within treatment. 
d
 different from week 2 within treatment 
(ANOVA p<0.05). 
Baseline 101.6 ± 2.4 2.95 ± 0.11 343 ± 13.1 51.3 ± 1.1
Week 1 NR+PL 99.4 ± 4.0 2.82 ± 0.12 357 ± 16.5 54.5 ± 1.0
IR+PL 85.5 ± 2.4
b
2.46 ± 0.07
b
411 ± 11.4
b
55.3 ± 0.9
IR+RIS 100.1 ± 2.6 2.84 ± 0.06 349 ± 9.4 52.8 ± 1.0
Week 2 NR+PL 96.7 ± 3.3 2.77 ± 0.07 362 ± 9.8 54.3 ± 1.5
IR+PL 78.1 ± 2.9
b
2.44 ± 0.08
b
410 ± 13.8
b
52.5 ± 1.4
IR+RIS 96.7 ± 2.7 2.89 ± 0.08 352 ± 11.4 52.4 ± 1.0
Week 3 NR+PL 95.5 ± 2.4 2.61 ± 0.07 384 ± 10.5 54.4 ± 1.0
IR+PL 75.4 ± 2.6
b,c
2.52 ± 0.10 400 ± 16.3 54.1 ± 1.5
IR+RIS 108.4 ± 2.0
b,d
2.81 ± 0.07 359 ± 10.1 53.6 ± 1.4
vBMD
(mg HA/cm
3
)
Tb.N
(1/mm)
Tb.Sp
(µm)
Tb.Th
(µm)
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Within time points, irradiated animals (IR+PL) showed significant changes in:  
BV/TV (-22%), Conn.Dens (-43%; Figure 3.2), SMI (+9%; Figure 3.3), vBMD (-14%), 
Tb.N (-13%; Table 3.2), and Tb.Sp (+15%; Table 3.2) at 1 week; BV/TV (-25%), 
Conn.Dens (-40%), vBMD (-19%), Tb.N (-12%) and Tb.Sp (+13%) at 2 weeks; and  
BV/TV (-32%), Conn.Dens (-53%), SMI (+12%), and vBMD (-21%) at 3 weeks relative 
to non-irradiated controls (NR+PL).  Administration of risedronate (IR+RIS) increased 
BV/TV (+21%), Conn.Dens (+36%), and vBMD (+13%) at 3 weeks relative to NR+PL.  
 
 
Figure 3.2. Trabecular connectivity of proximal tibia. 
 
Notes:  * different from NR+PL within time point (ANOVA p<0.05). 
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Figure 3.3. Structural model index of proximal tibia. 
 
Notes:  * different from NR+PL within time point (ANOVA p<0.05).  
 
 
 
3.4.2.2 Distal Femur 
Analysis within treatments across time identified significant changes in Tb.N (-
7%; Table 3.3) and Tb.Sp (+8%; Table 3.3) at 3 weeks in non-irradiated controls 
(NR+PL) relative to baseline.  Within irradiated-only animals (IR+PL), Tb.Sp (+6%) was 
significantly higher at week 3 compared to week 1.  At week 3, irradiated animals treated 
with risedronate (IR+RIS) showed significant changes in Conn.Dens (+55%; Figure 3.5) 
and SMI (-9%; Figure 3.6) relative to week 1, as well as BV/TV (+29%; Figure 3.4), 
Conn.Dens (+55%), SMI (-8%), and vBMD (+29%; Table 3.3) relative to week 2. 
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Table 3.3. Trabecular bone properties of distal femur from µCT. 
 
Notes:  All data given as mean ± SEM. 
a
 different from baseline within NR+PL. 
 
b
 different from NR+PL within time point. 
c
 different from week 1 within treatment. 
d
 different from week 2 within treatment (ANOVA p<0.05). 
 
 
Figure 3.4. Trabecular bone volume of distal femur. 
 
Notes:  * different from NR+PL within time point. # different from week 2 within 
treatment (ANOVA p<0.05). % difference given relative to NR+PL. 
Baseline 49.0 ± 4.5 3.21 ± 0.05 311 ± 4.2 36.9 ± 1.2
Week 1 NR+PL 41.0 ± 3.5 3.17 ± 0.06 317 ± 6.3 37.1 ± 1.4
IR+PL 25.2 ± 2.5
b
2.95 ± 0.05
b
341 ± 5.5
b
34.6 ± 1.0
IR+RIS 54.2 ± 3.4
b
3.28 ± 0.06 306 ± 5.5 38.2 ± 1.3
Week 2 NR+PL 43.7 ± 2.3 3.07 ± 0.04 326 ± 3.8 37.1 ± 1.4
IR+PL 24.4 ± 2.9
b
2.81 ± 0.04
b
359 ± 4.9
b
36.0 ± 1.2
IR+RIS 47.5 ± 3.2 3.21 ± 0.05 313 ± 4.5 37.1 ± 0.9
Week 3 NR+PL 39.6 ± 4.2 2.99 ± 0.05 a 336 ± 5.5 a 37.2 ± 1.3
IR+PL 24.4 ± 2.8
b
2.81 ± 0.05
b
360 ± 5.9
b,c
34.9 ± 1.9
IR+RIS 61.4 ± 3.9
b,d
3.29 ± 0.06
b
304 ± 5.5
b
39.1 ± 1.1
vBMD
(mg HA/cm
3
)
Tb.N
(1/mm)
Tb.Sp
(µm)
Tb.Th
(µm)
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Within time points, irradiated animals (IR+PL) showed significant changes in:  
BV/TV (-32%), vBMD (-39%), Tb.N (-7%), and Tb.Sp (+7%) at 1 week; BV/TV (-39%), 
Conn.Dens (-67%), SMI (+15%), vBMD (-44%), Tb.N (-8%), and Tb.Sp (+10%) at 2 
weeks; and BV/TV (-43%), Conn.Dens (-65%), SMI (+15%), vBMD (-38%), Tb.N (-
6%), and Tb.Sp (+7%) at 3 weeks relative to non-irradiated controls (NR+PL).  
Risedronate treated animals (IR+RIS) showed significant changes in vBMD (+32%) at 
week 1, and BV/TV (+50%), Conn.Dens (+134%), SMI (-10%), vBMD (+55%), Tb.N 
(+10%), and Tb.Sp (-9%) at week 3 relative to non-irradiated controls (NR+PL). 
 
 
Figure 3.5. Trabecular connectivity of distal femur. 
 
Notes:  * different from NR+PL with time point. + different from week 1 within 
treatment. # different from week 2 within treatment (ANOVA p<0.05). % difference given 
relative to NR+PL. 
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Figure 3.6. Structural model index of distal femur. 
 
Notes:  * different from NR+PL with time point. + different from week 1 within 
treatment. # different from week 2 within treatment (ANOVA p<0.05). % difference given 
relative to NR+PL. 
 
 
3.4.2.3 5th Lumbar Vertebra 
Analysis within treatments across time identified significant changes in: BV/TV 
(Figure 3.7) at weeks 2 (-9%) and 3 (-11%); SMI (Figure 3.9) at weeks 2 (+69%) and 3 
(+83%); and vBMD (Table 3.4) at weeks 1 (-8%), 2 (-10%), and 3 (-10%) in non-
irradiated animals (NR+PL) relative to baseline controls.  Additionally, these animals 
showed significant changes in Conn.Dens (+27%; Figure 3.8), SMI (+45%), and Tb.Th (-
6%; Table 3.4) at week 3 compared to week 1.  Within irradiated animals (IR+PL), 
significant changes in vBMD were identified at 2 (-8%) and 3 (-8%) weeks relative to 1 
week.  Irradiated animals treated with risedronate (IR+RIS) showed significant changes 
in BV/TV (+7%) at week 3 compared to week 2. 
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Figure 3.7. Trabecular bone volume of L5 vertebra. 
 
Notes:  $ different from baseline within NR+PL. * different from NR+PL within time 
point. # different from week 2 within treatment (ANOVA p<0.05). % difference given 
relative to NR+PL. 
 
Figure 3.8. Trabecular connectivity of L5 vertebra. 
 
Notes:  * different from NR+PL within time point (ANOVA p<0.05). 
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Analysis within time points revealed significant changes in:  BV/TV (-9%) and 
SMI (+70%) at 1 week; BV/TV (-15%), SMI (+48%), vBMD (-10%), Tb.N (-7%; Table 
3.4), and Tb.Sp (+8%; Table 3.4) at 2 weeks; and BV/TV (-11%), Conn.Dens (-21%), 
SMI (+34%), vBMD (-8%), Tb.N (-9%), and Tb.Sp (+10%) within irradiated animals 
(IR+PL) relative to non-irradiated controls (NR+PL).  Irradiated animals treated with 
risedronate (IR+RIS) showed significant changes in:  BV/TV (+15%), SMI (-48%), 
vBMD (+15%), and Tb.Th (+7%) at 1 week; BV/TV (+14%), SMI (-48%), vBMD 
(+12%), and Tb.Th (+6%) at 2 weeks; and BV/TV (+25%), SMI (-74%), vBMD (+15%), 
and Tb.Th (+12%) at 3 weeks compared to non-irradiated controls (NR+PL). 
 
 
Table 3.4. Trabecular bone properties of L5 vertebra from µCT. 
 
Notes:  All data given as mean ± SEM. 
a
 different from baseline within NR+PL. 
 
b
 different from NR+PL within time point. 
c
 different from week 1 within treatment. 
 (ANOVA p<0.05). 
Baseline 292.5 ± 5.4 6.63 ± 0.07 144 ± 1.5 45.3 ± 0.9
Week 1 NR+PL 268.0 ± 7.7 a 6.26 ± 0.08 154 ± 3.0 46.2 ± 0.5
IR+PL 259.8 ± 4.4 6.25 ± 0.09 155 ± 2.6 45.7 ± 0.5
IR+RIS 308.1 ± 5.0
b
6.49 ± 0.12 146 ± 3.4 49.2 ± 0.6
b
Week 2 NR+PL 263.6 ± 5.2 a 6.46 ± 0.12 149 ± 2.9 44.6 ± 0.7
IR+PL 238.6 ± 6.0
b,c
6.04 ± 0.07
b
161 ± 2.4
b
43.7 ± 0.8
IR+RIS 296.0 ± 4.4
b,c
6.51 ± 0.12 145 ± 3.1 47.4 ± 0.5
b
Week 3 NR+PL 262.0 ± 5.7 a 6.52 ± 0.14 150 ± 3.7 43.2 ± 0.5 c
IR+PL 239.9 ± 6.5
b,c
5.96 ± 0.13
b
164 ± 3.9
b
44.7 ± 0.5
IR+RIS 302.2 ± 3.8
b,c
6.54 ± 0.10 145 ± 2.8 48.5 ± 0.6
b
vBMD
(mg HA/cm
3
)
Tb.N
(1/mm)
Tb.Sp
(µm)
Tb.Th
(µm)
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Figure 3.9. Structural model index of L5 vertebra. 
 
Notes:  $ different from baseline within NR+PL. * different from NR+PL within time 
point. + different from week 1 within treatment (ANOVA p<0.05). % difference given 
relative to NR+PL. 
 
3.4.2.4 Femur Mid-diaphysis 
Within non-irradiated controls (NR+PL), Ct.Po was significantly different at 
weeks 1 (-25%) and 2 (-19%) when compared to the baseline control group.  There were 
no further differences between any groups within treatments or time points in BV, Ct.Po, 
or pMOI (Table 3.5). 
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Table 3.5. Cortical bone properties from µCT. 
 
Notes:  All data are given as mean ± SEM. 
a 
different from baseline within NR+PL 
(ANOVA p<0.05). 
 
3.4.3 Serum Chemistry 
TRAP5b data from the baseline controls and non-irradiated animals within weeks 
2 and 3 were found to be elevated (~37%) relative to non-irradiated controls from week 
1.  The differences were attributed to variability between the kits and equipment used.  
The results from these groups were normalized to the week 1 data prior to statistical 
comparison. No significant differences in TRAP5b concentration were found within 
treatments across the duration of the study.  Within time points, irradiated animals 
(IR+PL) showed a significant elevation in concentration at week 1 (+21%), and irradiated 
animals treated with risedronate (IR+RIS) showed significant reductions at week 1 (-
36%), week 2 (-35%), and week 3 (-37%) relative to non-irradiated controls (NR+PL) 
Baseline 216.7 ± 3.3 7.38 ± 0.36 323.8 ± 10.0
Week 1 NR+PL 226.0 ± 2.2 5.55 ± 0.22 a 333.0 ± 7.0
IR+PL 223.2 ± 3.2 5.58 ± 0.14 333.6 ± 11.9
IR+RIS 222.3 ± 2.6 5.86 ± 0.23 329.8 ± 8.1
Week 2 NR+PL 225.0 ± 2.3 5.95 ± 0.24 a 332.6 ± 6.0
IR+PL 216.6 ± 3.0 6.39 ± 0.28 323.3 ± 8.1
IR+RIS 219.7 ± 2.7 6.60 ± 0.20 324.6 ± 8.7
Week 3 NR+PL 226.5 ± 3.4 6.61 ± 0.32 331.5 ± 10.9
IR+PL 219.6 ± 3.4 6.31 ± 0.27 324.7 ± 8.5
IR+RIS 223.9 ± 3.2 6.58 ± 0.24 331.9 ± 9.5
BV
(mm
3
) * 10
3
Ct.Po
(%)
pMOI
(mm
4
) * 10
3
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(Table 3.6).  Analysis of serum osteocalcin concentration found no differences within 
treatments or within any time point. 
 
Table 3.6. Serum chemistry results. 
 
Notes:  All data are given as mean ± SEM. 
a
 different from NR+PL within time point 
(ANOVA p<0.05). 
 
 
3.5 Discussion 
Exposure to ionizing radiation is known to have negative effects on the skeletal 
system.  In the present study, we quantified the effects of low energy X-rays on 
trabecular and cortical bone properties at multiple skeletal sites and time points, and 
examined the effectiveness of risedronate administration at preventing post-irradiation 
bone atrophy.  A single, whole-body exposure to X-rays was found to significantly 
Baseline 6.60 ± 0.28 80.7 ± 11.6
Week 1 NR+PL 8.88 ± 0.53 151.6 ± 40.7
IR+PL 10.71 ± 0.56 a 128.5 ± 19.5
IR+RIS 5.66 ± 0.42 a 77.9 ± 18.1
Week 2 NR+PL 8.37 ± 0.88 110.7 ± 22.3
IR+PL 9.25 ± 0.57 128.1 ± 24.3
IR+RIS 5.43 ± 0.53 a 95.3 ± 20.1
Week 3 NR+PL 8.06 ± 0.58 83.0 ± 18.7
IR+PL 8.96 ± 0.87 112.1 ± 24.4
IR+RIS 5.07 ± 0.33 a 73.3 ± 10.7
TRAP5b
(U/L)
Osteocalcin
(ng/ml)
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deteriorate trabecular bone volume and micro-architecture as early as one week post-
exposure and elevate levels of serum bone resorption markers.  Further, administration of 
risedronate inhibited this degradation at all time points examined, indicating the observed 
loss may be osteoclast-regulated.   
Trabecular bone provides an important component to overall bone strength 
(Keaveny, Morgan et al. 2001; Bouxsein 2005).  The strength of trabecular bone depends 
heavily on density and architecture (Currey 2001), so any reductions in properties may 
adversely affect susceptibility to fracture.  Under normal conditions, trabeculae are 
structured as either parallel plates (SMI=0) or cylindrical rods (SMI=3).  SMI has been 
shown to have a negative correlation with bone volume (Hildebrand, Laib et al. 1999).  
L5 contained the highest percentage of trabecular bone of the sites examined, and thus 
had the lowest value of SMI.  The bone volume of the proximal tibia and distal femur 
were less than 1/3 that of the vertebra and were both largely composed of rod-like 
trabeculae.  The ratio of plates to rods remained relatively stable in these sites in non-
irradiated animals, as did associated measures of bone volume (BV/TV) and density 
(vBMD).  However, in the case of L5, bone volume and density continually decreased, 
and a number of trabeculae transitioned from plates to rods, although the overall plate-to-
rod ratio remained high.  This is expected, as skeletal properties have been shown to 
deteriorate with age once skeletal maturity is reached (Halloran, Ferguson et al. 2002; 
Glatt, Canalis et al. 2007). 
Although trabecular bone volume is generally the strongest indicator of strength 
(Hildebrand, Laib et al. 1999), connectivity plays a vital role in load distribution.  Loss of 
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individual struts and associated connectivity increases the likelihood of failure through 
buckling of the remaining elements, greatly reducing the strength of the bone (Silva and 
Gibson 1997).  Trabecular number and spacing generally remained unchanged in non-
irradiated animals, with the distal femur being the exception.  Declines of less than 10% 
at week 3 were seen in both parameters.  Accordingly, connectivity density remained 
stable in both the proximal tibia and distal femur, but was much less consistent within L5.  
It has been suggested that remodeling of trabeculae from plates to rods may artificially 
increase measures of connectivity (Campbell, Buie et al. 2008).  This may account for the 
inconsistency in connectivity within L5 at the early time points, as the upward trend in 
SMI had begun to level out by the end of the third week.   
Exposure to X-rays was found to affect many of the trabecular architectural 
parameters at the tibia, femur, and L5.  Substantial declines in bone volume and bone 
mineral density occurred continually throughout the study.  The majority of these 
changes were present after the first week, indicating the mechanism for bone loss was 
activated quickly following exposure.  Negative changes in trabecular number and 
spacing occurred early within the tibia and femur, as did the large reductions in overall 
connectivity density at these sites.  Within L5, the effects on trabecular number and 
spacing occurred much later, along with the changes in connectivity density.  Considering 
the relatively small changes in bone volume and bone mineral density in L5 when 
compared with the tibia and femur, the mechanism for bone loss may have a lower 
affinity for regions of high bone mass in the short-term, or the process may take 
significantly longer than at the lower density sites.  Conversely, the structural model 
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index of L5 decreased much more substantially than at the tibia and femur.  This is 
somewhat expected, as the individual struts within the tibia and femur were largely rod-
like in structure prior to irradiation.  L5 is composed of a much larger percentage of 
plate-like trabeculae, and therefore has a greater potential for remodeling into rod-like 
trabeculae. 
As mentioned earlier, deterioration of trabecular bone properties has a negative 
effect on overall bone strength (Currey 2001).  Radiotherapy has been implicated in 
fractures involving the ribs, clavicle, humerus, and hips (Howland, Loeffler et al. 1975; 
Pierce, Recht et al. 1992; Grigsby, Roberts et al. 1995; Bliss, Parsons et al. 1996; 
Mumber, Greven et al. 1997; Moreno, Clemente et al. 1999).  Significant declines in 
trabecular bone volume, bone mineral density, and associated measures of connectivity 
were identified within one week of radiation exposure.  These findings identify a 
potential cause for the noted increases in fracture risk following radiation treatment.  Loss 
of bone volume and subsequent weakening of the trabecular framework may lead to 
increases in fracture incidence. 
At all time points examined, risedronate inhibited bone loss, identifying an 
increase in bone resorption as the possible mechanism for radiation atrophy.  Treatment 
began immediately following irradiation, and the effects of risedronate were evident after 
one week.  Treated animals exhibited no changes in trabecular properties relative to 
controls during the first two weeks of treatment at the proximal tibia and distal femur.  
By the end of the third week, bone resorption was reduced enough to shift the balance 
within the normal turnover mechanism toward formation, resulting in a net increase in 
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trabecular properties.  The mice exhibited substantially increased trabecular bone volume, 
connectivity density, and bone mineral density.  Trabecular plate-to-rod ratio was also 
increased at the femur, although the overall ratio remained rod-like.  Improvements in 
trabecular number and spacing were also identified.  The effects were much smaller 
within L5, although changes were visible beginning at one week.  Bone volume and bone 
mineral density were increased while SMI was reduced as the trabeculae were remodeled 
from rods to plates.  Trabecular thickness was also affected, showing an increase at all 
time points. 
The geometric properties of cortical bone (cross-sectional area, moment of inertia, 
etc.) are the primary contributors to overall bone strength (Augat and Schorlemmer 
2006).  Therefore, any changes in cortical bone properties as measured via micro-
computed tomography may have a significant effect on susceptibility to fractures.  Prior 
studies have shown significant increases in cortical bone porosity and reductions in 
strength following high-dose irradiation (Sugimoto, Takahashi et al. 1991; Nyaruba, 
Yamamoto et al. 1998).  In both cases, these changes occurred following a single, high-
dose exposure (greater than 10 Gy).  Fractionation into doses less than 2 Gy mitigated the 
negative effects on strength (Nyaruba, Yamamoto et al. 1998), indicating lower doses 
may have no effect on cortical bone.  More recent studies have found no changes in 
cortical parameters following exposure to doses of 2 Gy or less (Hamilton, Pecaut et al. 
2006; Bandstra, Pecaut et al. 2008).  The results from the current study are consistent 
with these findings, as there were no significant differences in cortical volume, porosity, 
or polar moment of inertia between irradiated-only and non-irradiated animals.  Further, 
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risedronate administration has been shown to have minimal effects on measures of 
cortical thickness and porosity (Dufresne, Chmielewski et al. 2003).  Accordingly, no 
changes were observed in any of the measured cortical parameters between irradiated 
animals given risedronate and non-irradiated controls. 
Of further interest were the observed differences in cortical porosity between 
baseline animals and the non-irradiated controls from weeks 1 and 2.  Baseline animals 
exhibited relatively high values of porosity.  It should be noted that the standard deviation 
in these animals was higher than in any of the other study groups.  This, coupled with the 
lack of differences in polar moment of inertia and bone volume, indicate the porosity 
variations may be due to random biological differences within the baseline animals, as 
several samples exhibited porosity values over 20% higher than the mean. 
Animal mass was used as an indicator of overall animal health throughout the 
course of the study, as weight loss is a well-known side effect of exposure to ionizing 
radiation.  An overall reduction in body mass results in a reduction in loading on the 
skeleton.  According to Wolff’s Law, significant reduction in loading would likely lead to 
decreased bone volume and trabecular micro-architecture.  Irradiated-only animals at 
weeks 2 and 3 showed significant losses of mass.  In each case, the magnitude of the 
changes was approximately 0.5 grams.  Similarly, risedronate-treated animals showed 
only an increase in mass at week 1.  Despite these changes, there were no differences in 
initial or final masses between individual groups, indicating the noted deterioration 
following irradiation and subsequent maintenance with risedronate of trabecular bone 
architectural properties were not due to changes in skeletal loading. 
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The biological mechanisms leading to the observed radiation-induced bone loss 
have yet to be fully explored.  While past research has focused on the radiation effects on 
osteoblasts and vasculature (Mitchell and Logan 1998; Okunieff, Wang et al. 1998; Gal, 
Munoz-Antonia et al. 2000; Sakurai, Sawada et al. 2007), the present study indicates 
radiation atrophy may be osteoclast-regulated.  Elevated serum levels of tartrate-resistant 
acid phosphatase (TRAP5b) were found at one week post-exposure in irradiated-only 
animals, indicating an increase in the number of osteoclasts (Halleen, Tiitinen et al. 
2006).  Osteocalcin levels remained unchanged throughout the study.  By the end of the 
second week, TRAP5b levels were stabilized. This suggests a net increase in bone 
resorption occurred within the first several days post-exposure.  These findings are 
consistent with the microCT results, as the majority of the measured changes in 
trabecular volume and architecture occurred during the first week of the study.  
Considering the effectiveness of risedronate, an early increase in osteoclast activity is a 
likely contributor to radiation-induced bone loss. 
In summary, exposure to a single, whole-body dose of X-rays produced 
significant deterioration of trabecular bone volumetric and micro-architectural properties 
in skeletally mature mice with no associated changes in cortical bone properties.  Loss of 
trabecular bone was identified at the proximal tibia, distal femur, and fifth lumbar 
vertebra at all time points examined, with a large portion of the changes occurring within 
the first week post-exposure.  When considered with the increase in serum bone 
resorption markers seen at one week with no changes in bone formation markers, an early 
increase in osteoclast activity seems the likely the cause of radiation-induced bone loss.  
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Risedronate was proven effective at preventing trabecular bone deterioration, identifying 
a potential measure of preventing radiation-induced fractures.  Further examination is 
recommended to fully explore radiation effects on bone turnover and determine the most 
appropriate and effective route for preventing fractures. 
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CHAPTER 4 – CONCLUSIONS AND RECOMMENDATIONS 
 
4.1 Summary 
This research identified a substantial deterioration of trabecular bone micro-
architectural properties following exposure to a whole-body dose of radiation.  Measures 
of trabecular volume, density, number, and structure were affected within one week of 
irradiation at sites within both the appendicular and axial skeletons.  Cortical bone 
properties showed no effects from radiation.  Serum concentrations of bone resorption 
markers were elevated at one week post-irradiation.  Bisphosphonate treatment prevented 
trabecular bone loss at all sites examined and maintained associated architectural 
properties. 
 
4.2 Limitations and Recommendations 
The radiation source used in the present study operates at an energy level several 
orders or magnitude lower than those used in radiotherapy.  Radiation effects on bone are 
believed to be reduced when using sources operating at higher energy levels (Howland, 
Loeffler et al. 1975; Mitchell and Logan 1998).  Although the physics of low energy x-
rays is different, photon energy does not affect the biological response of normal tissue.  
However, as bone is a dense material that has received little study by radiation biologists, 
it is important to be cognizant of a potential energy effect.   A clinical radiation source 
should be used in future studies to eliminate any potential energy-level dependence of 
bone effects. 
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Typical radiotherapy regimens are localized to the tumor site and given in 
fractionated doses (National Cancer Institute 2007).  Future studies should involve a 
larger cumulative dose given in fractions to a specific site to model a typical tumor 
treatment cycle.  This can be accomplished through the use of shielding and/or focusing 
of the radiation beam using a clinical irradiator.  
Risedronate is currently approved for treatment of glucocorticoid-induced and 
post-menopausal osteoporosis as well as Paget’s disease.  The prescribed oral dose for 
osteoporosis patients is 5 mg/day, 35 mg/week, or 150 mg/month.  Although the 
pharmacokinetics of risedronate in mice are not fully understood, a dose of 70 µg/kg/day 
given orally is considered comparable (Sefc, Broulik et al. 2007).  Using a bioavailability 
of 0.63% (Crandall 2001), this equates to an approximate subcutaneous dose of 0.5 
µg/kg/day.  The dose administered in the current study (30 µg/kg every other day) was 
significantly larger, and more comparable (though still larger) to the dose prescribed to 
Paget’s disease patients (30 mg/day oral, ~3 µg/kg/day subcutaneous).  As such, the 
sparing effects of the drug on bone loss were likely exaggerated when considered in 
context with normal osteoporosis treatment regimens.  The effects of smaller doses that 
model those given osteoporosis patients should be examined in order to determine the 
minimum threshold for efficacy. 
Although the serum chemistry results indicate an increase in osteoclast activity, 
the radiation effects on individual cells are not examined.  Histological analysis is needed 
to quantify and qualify the changes in bone cell structure and number.  Additionally, 
dynamic histomorphometry is recommended to quantify both radiation and drug-induced 
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changes in bone formation and resorption rates.  These data along with results from the 
microCT analyses should be correlated with changes in whole bone strength as 
determined via mechanical testing. 
To more fully characterize the radiation effects on bone, both earlier and later 
time point examinations are needed.  The results from the present study indicate the 
mechanism for bone loss is activated within the first week post-exposure.  Earlier time 
points should be studied to determine the timeline when the changes to bone cells 
produce functional declines in bone architectural properties.  Additionally, time points 
after three weeks should be examined to determine if/when any natural bone loss 
recovery occurs. 
The results from this research have potential implications in the study of skeletal 
changes resulting from spaceflight.  In addition to the microgravity environment which is 
known to cause reductions in bone mass (Lang, LeBlanc et al. 2004), astronauts are 
exposed to multiple types of radiation, including protons and heavy ion particles (Todd 
2003), which may increase the magnitude of bone deterioration.  The effects of exposure 
to these types of radiation should examined to determine if specific radiation types are 
potentially more damaging to bone, and determine if any bone deterioration that is 
measured can be effectively treated. 
 
4.3 Conclusions 
The results from this research support earlier findings within our laboratory of an 
early increase in osteoclast activity following exposure to ionizing radiation.  Trabecular 
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bone deterioration can occur rapidly, leading to elevated levels of serum bone resorption 
markers at one week post-irradiation.  Bone formation appears unaffected in the short-
term.  Anti-resorptive therapy is effective at preventing radiation-induced bone loss, 
further supporting finds of increased osteoclast activity.  The results from this study and 
future studies incorporating the above recommendations will prove useful in determining 
the most effective method of preventing fractures resulting from radiotherapy, and lead to 
a higher quality of life for cancer survivors. 
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Appendix A 
 
Risedronate Dosing and Dilution 
 
Using information provided by Procter and Gamble, a risedronate dose of 30 µg/kg given 
every other day was chosen.  The drug was received in dry form in vials containing 5 mg 
samples. 
1.  Five ml of sterile PBS was added to the dry sample within one vial.  The solution 
was then vortexed for an appropriate time to allow the compound to dissolve into 
solution at a concentration of 1 mg/ml. 
2.  Four milliliters of the solution was pipetted from the vial and placed in a sterile 5 
ml tube (stock solution). 
3. The concentration of the injected dose was determined as follows based on a 
standard volume of 0.2 ml given to a 20 g animal: 
 30 
𝜇𝑔
𝑘𝑔
 ×  0.02 
𝑘𝑔
𝑚𝑜𝑢𝑠𝑒
 ×  
1 𝑚𝑜𝑢𝑠𝑒
0.2 𝑚𝑙
 ×  
103𝑚𝑔
106𝜇𝑔
 = 0.003 
𝑚𝑔
𝑚𝑙
 
4.  The injectable solution was then created from the stock solution through a series 
of dilutions as follows: 
 1 
𝑚𝑔
𝑚𝑙
 ×   𝐴 𝑚𝑙𝑠𝑡𝑜𝑐𝑘  =  0.1 
𝑚𝑔
𝑚𝑙
 ×  4 𝑚𝑙                 𝐴 = 0.4 𝑚𝑙𝑠𝑡𝑜𝑐𝑘 +  3.6 𝑚𝑙𝑃𝐵𝑆  
 0.1 
𝑚𝑔
𝑚𝑙
 ×   𝐵 𝑚𝑙𝐴 =  0.1 
𝑚𝑔
𝑚𝑙
 ×  4 𝑚𝑙               𝐵 = 0.4 𝑚𝑙𝐴 +  3.6 𝑚𝑙𝑃𝐵𝑆  
 0.01 
𝑚𝑔
𝑚𝑙
 ×   𝐶 𝑚𝑙𝐵 =  0.003 
𝑚𝑔
𝑚𝑙
 ×  4 𝑚𝑙           𝐶 = 1.2 𝑚𝑙𝐵 +  2.8 𝑚𝑙𝑃𝐵𝑆  
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5.  The volume of solution given to each animal was determined from mass (21 g 
animal received 0.21 ml, 22 g animal received 0.22 ml, etc). 
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Appendix B 
 
MicroCT Scanning and Analysis 
 
Site    Threshold  Sigma  Support 
Proximal tibia   365   1.2  2.0 
Distal femur   225   0.8  1.0 
L5 vertebra   220   0.8  1.0 
Femur mid-diaphysis  260   0.8  1.0 
 
Tube Setups 
       
Tibia     Femur    L5 vertebra 
 
1. Tibia:  Samples were cut ~1/3 distance from proximal end and stacked in pairs for 
4 levels (8 bones per tube).  The direction of the proximal end was alternated 
within each level.  Foam was used for support and separation. P denotes the 
proximal end. 
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2. Femur:  Samples were placed within circular foam discs as shown with the distal 
end towards the bottom.  Three discs were placed within the tube for scanning, for 
a total of 12 bones per tube.  X denotes a marker used for identification. 
3. L5:  Samples were placed as shown in pairs for 2 levels (4 per tube), alternating 
the direction of the ribs within each level.  Foam was used for support and 
separation.  R denotes the position of the ribs.  
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